Experimental treatment directly kills prostate tumor cells while reawakening antitumor immunity

by Weill Cornell Medical College

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Associate Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing antitumor immunity, according to a preclinical study led by investigators at Weill Cornell Medicine and the Cornell Duffield College of Engineering.

The particles, derived from silicon dioxide, a common component of healthy foods or fossilized sedimentary structures from single-celled organisms, induced several complete remissions of aggressive tumors in mouse models, supporting further investigation of their use in clinical trials.

Originally developed for medical imaging applications, these particles, known as ultrasmall fluorescent core-shell silica nanoparticles, or Cornell Prime dots (C' dots), have progressed into advanced-phase clinical trials for image-guided surgery and therapeutic applications. In recent years, the researchers have found that the C' dots on their own can exert therapeutic effects against cancer cells while sparing healthy cells.

In the new study, published in Cancer Research, the researchers evaluated the particles' effects in mouse models of aggressive prostate cancer. They showed that the particles make tumor cells highly susceptible to a powerful self-destruct process and simultaneously convert the normally inactive, "cold" prostate tumor immune microenvironment into a "hot" one featuring strong antitumor immune activity—which can dramatically enhance the effects of other immunotherapies.

"We're very encouraged by these results; a treatment that directly induces tumor-cell death while transforming the immune microenvironment, as this does, would represent a new clinical paradigm," said study senior author Dr. Michelle Bradbury, the Endowed Professor of Imaging Research in Radiology and director of the Molecular Imaging Innovations Institute at Weill Cornell Medicine and a neuroradiologist at NewYork-Presbyterian/Weill Cornell Medical Center.

The study was part of a long-term collaboration between Bradbury's laboratory and the laboratory of co-corresponding author Dr. Ulrich Wiesner, the Spencer T. Olin Professor in the Department of Materials Science and Engineering and a professor in the Department of Design Tech in the College of Architecture, Art, and Planning.

How the particles work

As detailed in the study, the unusual effects of the C' dots include pushing prostate tumor cells toward a self-destruct mode called "ferroptosis," in which the overwhelming oxidation of molecules in the cells, especially the fat-related molecules that make up cell membranes, leads to the degradation of those membranes.

Precisely how the particles trigger ferroptosis remains unclear, but the researchers have found evidence that the particles, originally designed as carriers for imaging agents, often pick up positively charged iron ions in the bloodstream and transport those reactive cargoes inside tumor cells—where they ultimately can help catalyze runaway oxidation.

The C' dots had numerous immunological impacts, including the conversion of T cells, macrophages and other immune cells in the tumor vicinity from inert or actively immunosuppressive modes to robust antitumor activity.

These results led to C' dots sensitizing tumors to clinically approved anticancer immunotherapies. The experiments also revealed extensive growth-inhibiting metabolic disruptions in different cell populations within the tumor microenvironment.

The silica particles were specifically targeted to prostate tumor cells by a molecule that homes in on a prostate cell surface protein called PSMA, but even in nonprostate tissues where the particles were briefly concentrated, such as the spleen, there was no sign of toxicity.

"It seems unreal—how is it possible that, rather than a single pathway, we see all these effects happening simultaneously and only in tumors and not in healthy tissues?" Wiesner said. "I have to wonder whether ultrasmall silica's very early and ubiquitous presence in the environment and foods like leafy greens or cereal grains has given it a connection to biology that we're only beginning to glimpse."

Strong results in mice

The most striking results came when the researchers conducted survival experiments in mice with aggressive prostate cancer.

The C' dots on their own, and immunotherapies on their own, moderately extended survival compared with no treatment. But the combination of silica particles with an immunotherapy called immune checkpoint blockade synergistically resulted in complete or near-complete remissions and indefinite survival in four out of 10 mice treated this way.

Adding a third treatment called CSF-1R blockade, which targets tumor-associated macrophages, yielded five out of 10 complete remissions.

"We think there's nothing else out there that has such a strong and durable tumor-growth-suppressing effect," Bradbury said.

"One of the most intriguing aspects of this work is the convergence of direct tumor cell killing with broad immune remodeling," said study co-author Dr. Jedd Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center, professor of medicine at Weill Cornell Medicine, director of the Parker Institute for Cancer Immunotherapy at Weill Cornell Medicine Meyer Cancer Center and an oncologist at NewYork-Presbyterian/Weill Cornell Medical Center.

"By creating conditions that support a more effective antitumor immune response, these particles may help unlock the full potential of immunotherapy in prostate cancer, where durable responses have historically been difficult to achieve."

Next steps toward trials

Bradbury and her colleagues also recognized the contributions of the study's co-first authors, Drs. Nabil Siddiqui, Li Zhang and Gabriel DeLeon, who led many of the biological, mechanistic and translational studies, as well as the graduate students in Wiesner's laboratory, Nada Naguib and Rachel Lee, whose precision synthesis and characterization of particle batches made the work possible.

"This study reflects years of collaborative effort across multiple laboratories and would not have been possible without the dedication, creativity and perseverance of this tremendous research team that helped drive the science forward," she said.

The researchers are continuing to explore these ultrasmall core-shell silica particles as a new class of anticancer therapeutics that can simultaneously modulate inflammatory, immune and metabolic pathways, with the ultimate goal of evaluating their safety and efficacy in clinical trials.

Publication details

Cancer Research (2026).

Journal information: Cancer Research

Key medical concepts

Prostate CarcinomaCheckpoint Blockade ImmunotherapyFerroptosis

Clinical categories

OncologyUrology Provided by Weill Cornell Medical College Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Experimental treatment directly kills prostate tumor cells while reawakening antitumor immunity (2026, June 15) retrieved 15 June 2026 from https://medicalxpress.com/news/2026-06-experimental-treatment-prostate-tumor-cells.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.